The new adsorbing membrane for continuous renal replacement therapy (CRRT), oXiris, can reduce plasma cytokines and endotoxins in septic shock patients with severe acute kidney injury, compared with standard membranes. However, its hemodynamic stability or benefits have not been thoroughly evaluated although this is reasonable.
Aged ≥ 18 years
Sepsis related acute kidney injury requiring continuous renal replacement therapy
None
Adult patients who have severe acute kidney injury and require continuous renal replacement therapy because of hemodynamic instability.
Case-control
Prospective
oXiris membrane
DevicePerform continuous renal replacement therapy with oXiris membrane
Polysulfone membrane
DevicePerform continuous renal replacement therapy with polysulfone membrane
Rate of all-cause mortality
Risk of all-cause mortality
Occurrence rates of ventricular tachycardia, intradialytic hypotension
Risk of ventricular tachycardia, intradialytic hypotension
Click on the lead sponsor to view all of their trials.
